For Immediate Release: 1pm - Tuesday 29th May 2007
ValiRx and Bridgetech form a strategic alliance to foster technology transfer b
etween Europe and Greater China
ValiRx Plc ("ValiRx") (AIM: VAL), the cancer therapeutics company and
Bridgetech Holdings International Inc. ("Bridgetech") (OTCBB: BGTH.PK), a
company focused on maximizing the potential of emerging healthcare products and
services in the U.S. and Asian markets, today announce that they have signed a
strategic alliance agreement. The agreement governs cooperative efforts in
creating and exploiting market and technology transfer initiatives between
Europe and Greater China.
"Bridgetech's ability to excel in the marketplace is, in no small part, thanks
to our prestigious set of global alliance partners. ValiRx is one of the
European industry leaders in cancer therapeutics and diagnostics," stated
Michael Chermak, Chairman and CEO of Bridgetech. "We seek to identify
innovative oncology products that fit our Greater China market strategy."
Dr Satu Vainikka, CEO of ValiRx, added "ValiRx is excited to execute this
alliance agreement with Bridgetech to accelerate the process of taking
knowledge generated in laboratories and turning them into market-ready
products."
Tony Moore, Chairman of ValiRx and MCC Global said "MCC is delighted that
following the recent strategic agreement between Bridgetech and MCC, we have
been able to facilitate the introduction that has led to this alliance."
---ENDS---
About Bridgetech Holdings International, Inc.
Bridgetech is leveraging its extensive network of relationships in China and
the U.S. to capitalize on the demand for Western healthcare in Greater China.
The company is bringing emerging drugs, devices and diagnostics to Greater
China, with an initial focus on oncology. For additional information, please
visit Bridgetech at www.bthi.com.
About ValiRx Plc
ValiRx is a biopharmaceutical development company that is building a portfolio
of complementary cancer-related therapeutic and diagnostic technologies. It
currently holds stakes in Cronos Therapeutics Limited ("Cronos") and
Morphogenesis Inc;
* Cronos holds licenses to two innovative and potentially market changing
technologies, GeneICE and HyperGenomics;
* Morphogenesis Inc. is developing a portfolio of cell therapy products for
the treatment of chronic disorders. Its most advanced product, being
ImmuneFx(tm) for which it recently received a patent from the US patent
office.
For additional information, please visit ValiRx at www.valirx.com
About MCC Global
MCC Global NV is a global private equity merchant bank specializing in
providing strategic and financial advisory an investment services to emerging
companies in specific industry sectors such as healthcare, energy renewables,
media, real estate, hospitality and lifestyles and fashion and beauty. MCC
Global NV (www.mccglobal.com) is listed on the Frankfurt Stock Exchange
Geregelter Markt, ticker IFQ2.
For Further Information
ValiRx:
Dr Satu Vainikka (CEO) +44 203 008 4416
Toby Hall / Jade Mamarbachi (gth media) +44 207 153 8035
David Youngman (WH Ireland) +44 161 832 2174
Bridgetech:
Vince Heald (Beck Ellman Heald) +1 (858) 453 9600
MCC Global
Dana Smith (Investor Relations) +1 (801) 816 2500
Translate
